AptaBio Therapeutics Inc (293780) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has a cash flow conversion efficiency ratio of -0.061x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.73 Billion ≈ $-1.85 Million USD) by net assets (₩44.61 Billion ≈ $30.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of AptaBio Therapeutics Inc for the company's overall valuation and market capitalisation.
AptaBio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how AptaBio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AptaBio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AptaBio Therapeutics Inc ranked by their cash flow conversion efficiency. See 293780 operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanyang Digitech Co. Ltd
KQ:078350
|
0.085x |
|
CF Acquisition VII Corp
NASDAQ:CFFS
|
N/A |
|
Maiden Holdings Ltd
NASDAQ:MHLD
|
-0.562x |
|
Caisse Regionale de Credit Agricole Mutuel Loire HauteLoire
PA:CRLO
|
0.036x |
|
Eusu Holdings
KO:000700
|
0.037x |
|
CONDOR ENERGIES INC.
F:WQ6
|
0.162x |
|
ReaLy Development & Construction
TWO:2596
|
0.055x |
|
Gandhi Special Tubes Limited
NSE:GANDHITUBE
|
0.082x |
Annual Cash Flow Conversion Efficiency for AptaBio Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of AptaBio Therapeutics Inc from 2017 to 2024. View AptaBio Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩54.20 Billion ≈ $36.73 Million |
₩-12.16 Billion ≈ $-8.24 Million |
-0.224x | +2.32% |
| 2023-12-31 | ₩61.36 Billion ≈ $41.59 Million |
₩-14.10 Billion ≈ $-9.55 Million |
-0.230x | -76.05% |
| 2022-12-31 | ₩52.37 Billion ≈ $35.49 Million |
₩-6.83 Billion ≈ $-4.63 Million |
-0.130x | +9.57% |
| 2021-12-31 | ₩61.67 Billion ≈ $41.79 Million |
₩-8.90 Billion ≈ $-6.03 Million |
-0.144x | -174.59% |
| 2020-12-31 | ₩72.04 Billion ≈ $48.82 Million |
₩-3.79 Billion ≈ $-2.57 Million |
-0.053x | +34.20% |
| 2019-12-31 | ₩75.16 Billion ≈ $50.93 Million |
₩-6.00 Billion ≈ $-4.07 Million |
-0.080x | +16.38% |
| 2018-12-31 | ₩18.31 Billion ≈ $12.41 Million |
₩-1.75 Billion ≈ $-1.19 Million |
-0.095x | -268.19% |
| 2017-12-31 | ₩-31.54 Billion ≈ $-21.37 Million |
₩-1.79 Billion ≈ $-1.21 Million |
0.057x | -- |
About AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more